|
|
b'Age: 18-70 years old (Include both values); 2. Patients with histopathologically or' |
|
|
|
|
|
b'cytologically confirmed advanced solid tumor (not necessary to have measurable lesions); 3.' |
|
|
|
|
|
b'Refractory or intolerant to standard treatment regimens, or no effective standard treatment' |
|
|
|
|
|
b'regimens available, or the patients refused to use standard treatment plan 4. ECOG PS' |
|
|
|
|
|
b'core: 0-1; 5. Expected survival \\u2265 3 months; 6. Subjects have recovered from other' |
|
|
|
|
|
b'treatments, at least 6 weeks since the last use of nitrosourea or mitomycin; at least 4' |
|
|
|
|
|
b'weeks since the last use of small molecule targeted therapy; at least 5 half-lives since' |
|
|
|
|
|
b'the last use of biological macromolecular therapy; at least 4 weeks since radiotherapy or' |
|
|
|
|
|
b'urgery; at least 4 weeks since the last use of other cytotoxic or cytostatic drugs; 7.' |
|
|
|
|
|
b'Major organs must function normally, meeting the following criteria:' |
|
|
|
|
|
b'Hematology (no blood transfusion or blood products within the last 14 days, not' |
|
|
|
|
|
b'corrected with G-CSF or other hematopoietic colony-stimulating factors):' |
|
|
|
|
|
b'HB\\u2265100 g/L;' |
|
|
|
|
|
b'ANC\\u22651.5\\xd7109/L;' |
|
|
|
|
|
b'PLT\\u226590\\xd7109/L;' |
|
|
|
|
|
b'Blood biochemistry:' |
|
|
|
|
|
b'TBIL\\u2264 1.25\\xd7ULN;' |
|
|
|
|
|
b'ALT and AST\\u22642.5\\xd7ULN;' |
|
|
|
|
|
b'AKPALP\\u22642.5\\xd7ULN;' |
|
|
|
|
|
b'Serum Cr \\u2264 1.5 \\xd7 ULN or endogenous CrCl \\u2265 60 mL/min (Cockcroft-Gault formula);' |
|
|
|
|
|
b'Albumin > 30 g/L; 8. Sign the ICF voluntarily, have good compliance, corporate' |
|
|
|
|
|
b'with follow-up visits, and follow the study requirements.' |
|
|
|
|
|
b'Gastric cancer; tumors with risk of bleeding which researchers evaluated. 2.'
|
|
|
|
|
|
b'Active brain metastasis (medically uncontrolled); 3. Symptomatic third space'
|
|
|
|
|
|
b'fluid that cannot be controlled by drainage or other methods; 4. Dysphagia,'
|
|
|
|
|
|
b'chronic diarrhea, or other factors affecting drug intake and absorption; 5.'
|
|
|
|
|
|
b'Uncontrolled hypertension; 6. Heart rate < 60, Grade II or greater myocardial'
|
|
|
|
|
|
b'ischemia or myocardial infarction, uncontrolled arrhythmias (QTc interval \\u2265 450'
|
|
|
|
|
|
b'ms in males and \\u2265 470 ms in females); 7. Contraindications to Repaglinide and'
|
|
|
|
|
|
b'Bupropion; 8. NYHA Class III-IV cardiac insufficiency or left ventricular'
|
|
|
|
|
|
b'ejection fraction (LVEF) < 50% by echocardiography; 9.Abnormal coagulation'
|
|
|
|
|
|
b'function (INR > 1.5 or prothrombin time (PT) > ULN + 4 s or APTT > 1.5 ULN),'
|
|
|
|
|
|
b'bleeding tendency or who are currently receiving thrombolytics; 10.'
|
|
|
|
|
|
b'Arterial/venous thrombosis within 6 months prior to the first dose; 11.Hemorrhage'
|
|
|
|
|
|
b'and thrombophilia; 12. Major surgery or with severe traumatic injury, fracture,'
|
|
|
|
|
|
b'or ulcer within 4 weeks prior to the first dose; 13. Abdominal fistula,'
|
|
|
|
|
|
b'gastrointestinal perforation or abdominal abscess within 6 months prior to the'
|
|
|
|
|
|
b'first dose; 14. Urine protein \\u2265 ++ or 24 h urine protein \\u2265 1.0 g as indicated by'
|
|
|
|
|
|
b'urinalysis; 15. Treatment with steroids for more than 50 days, or requires'
|
|
|
|
|
|
b'chronic steroid use; 16. Use of study drugs in other clinical trials within 4'
|
|
|
|
|
|
b'weeks prior to the first dose; 27. Use of drugs affected gastric acid secretion'
|
|
|
|
|
|
b'or cytochrome enzyme CYP2C8\\u3001CYP2B6\\u3001CYP2D6\\u3001CYP3A and transporter OATP1B1 within 4'
|
|
|
|
|
|
b'weeks prior to the first dose; 18. Use of Chinese medicine, traditional Chinese'
|
|
|
|
|
|
b'medicine preparation or health products within 2 weeks prior to the first dose;'
|
|
|
|
|
|
b'Unable to hold drugs that may prolong QT interval during the study (such as'
|
|
|
|
|
|
b'antiarrhythmics); 20.Drug abuse within 12 months before the first dose or'
|
|
|
|
|
|
b'positive drug screening; 21. Drinking or smoking addiction ; 22.Other factors'
|
|
|
|
|
|
b'affecting drug absorption, distribution, metabolism, excretion Within 48 hours\\uff1b'
|
|
|
|
|
|
b'Active hepatitis B (HBV-DNA\\u2265104 or 2000IU/ml) or C (Hepatitis C antibodies are'
|
|
|
|
|
|
b'positive and HCV-RNA is above the detection limit of the analytical method); 24.'
|
|
|
|
|
|
b'Active infection requiring antimicrobial therapies (such as antibacterials,'
|
|
|
|
|
|
b'antivirals, or antifungals); 25. Immunodeficiency, including positive results of'
|
|
|
|
|
|
b'HIV test or other acquired or congenital immunodeficiencies, or a history of'
|
|
|
|
|
|
b'organ transplantation; 26. Allergic constitution, or known allergies to drug'
|
|
|
|
|
|
b'components used in this study; 27. Pregnant or lactating women; 28. Other factors'
|
|
|
|
|
|
b'that may affect the progress or the conclusion of the study, as determined by the'
|
|
|
|
|
|
b'investigator.'
|
|
|
|